Abstract
AbstractBackgroundAfter percutaneous coronary intervention (PCI), clopidogrel resistant patients are at an increased risk of major adverse cardiovascular and cerebrovascular events (MACCEs). We aimed to assess whether genotype-guided selection of oral antiplatelet drugs using a clinical decision support (CDS) algorithm reduces the occurrence of these ischemic events and improves outcomes among Caribbean Hispanic patients from Puerto Rico, who are underrepresented in clinical pharmacogenomic (PGx)-guided implementation studies.MethodsIndividual platelet function testing (PRU) measures,CYP2C19*2 andPON1rs662 genotypes, clinical and demographic data from 8 medical facilities were included. Patients were separated into standard of care (SoC) and genotype-guided groups (150 each). Risk scores were calculated based on a previously developed CDS risk prediction algorithm designed to make actionable treatment recommendations for each patient. Alternative therapy with ticagrelor was recommended for patients with a high risk score ≥2. Statistical associations between patient time free of MACCEs and predictor variables (i.e., treatment groups, risk scores) were tested in this population using Kaplan-Meier survival analyses and Cox proportional-hazards regression models.ResultsMedian age of participants is 67 years; BMI: 27.8; 48% women; 14% smokers; 59% with type-2 diabetes mellitus (T2DM). Among patients with high-risk scores who were free from MACCE events 6 months after coronary stenting, genotype-driven guidance of antiplatelet therapy showed superiority over SoC in terms of reducing the incidence rate of atherothrombotic events.ConclusionsThe clinical utility of our PGx-driven CDS algorithm to reduce the incidence rate of MACCEs among post-PCI Caribbean Hispanic patients on clopidogrel was externally demonstrated.Clinical Trial Registration Unique IdentifierNCT03419325
Publisher
Cold Spring Harbor Laboratory
Reference31 articles.
1. Centers for Disease Control and Prevention. (2022, October 14). Heart disease facts. Centers for Disease Control and Prevention. Retrieved May 3, 2023, from https://www.cdc.gov/heartdisease/facts.htm#:∼:text=due%20to%20death.-,Coronary%20Artery%20Disease,killing%20382%2C820%20people%20in%202020.&text=About%2020.1%20million%20adults%20age,have%20CAD%20(about%207.2%25).&text=In%202020%2C%20about%202%20in,less%
2. Heart Disease and Stroke Statistics—2021 Update
3. Prevalence of Major Cardiovascular Risk Factors and Cardiovascular Diseases Among Hispanic/Latino Individuals of Diverse Backgrounds in the United States
4. Brook Stony. Cardiovascular Disease in Hispanics/Latinos in the United States and on Long Island. Renaissance School of Medicine at Stony Brook University. 2019 Retrieved from https://renaissance.stonybrookmedicine.edu/surgery/blog/cardiovascular-disease-in-hispanics-latinos
5. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines